Trump Targets 340B Fraud as Medicare Scandals Mount
Trump administration pushes to crack down on 340B Medicare fraud as cases of overbilling and luxury spending emerge.
4 min read
The Trump administration is intensifying its efforts to combat widespread fraud and misuse within the 340B Drug Pricing Program, a federal initiative designed to assist nonprofit hospitals in providing affordable medications to low-income patients. Recent revelations of massive overbilling, kickbacks, and extravagant spending by entities participating in the program have drawn public scrutiny and calls for stricter oversight.
A Growing Crisis of Fraud and Waste
According to recent reports, the 340B program—intended to support safety-net hospitals—has become a target for exploitation, with entities engaging in mass fraud. One case has brought the issue into sharp focus: Jean Jethro Alexandre, a Haitian foreign national, allegedly used the 340B program to defraud Medicare, Medicaid, and private insurance of over $58 million. The funds were then used to fund a life of luxury, including high-end vehicles, a mansion near Miami, and other properties.
Alexandre allegedly recruited fake patients, paid them kickbacks to accept fraudulent prescriptions, and then pocketed the reimbursements. This case highlights the brazen nature of the abuse, as the program, which was meant to serve vulnerable populations, has instead become a mechanism for personal enrichment.
Politicians and Their Families Tied to the Fraud
Another alarming case involves Ilhan Omar’s sister, Sahra Noor, who ran a 340B clinic known as the People’s Center Clinics & Services. Omar boasted about securing $2.2 million for the clinic, and recent reports suggest that a raid on her home was triggered by a text message on her sister’s phone. This incident has raised concerns about the involvement of political figures in the misuse of the program.
These cases are not isolated. They are part of a broader trend of waste, fraud, and abuse within the 340B program. Law enforcement agencies have begun to take notice, with multiple entities facing legal action for their alleged misconduct. For example, New York-Presbyterian/Brooklyn Methodist Hospital agreed to pay $17.3 million to settle allegations of paying unlawful kickbacks to physicians at a chemotherapy infusion center. Similarly, Virginia Commonwealth University’s Health System Authority agreed to pay nearly $4 million after audits found that federal health care payors had been overbilled for radiation oncology services.
Exploiting the System for Profit
While the 340B program was created to help nonprofit hospitals serve low-income patients by allowing them to purchase prescription medicines at steep discounts, the reality is that hospitals are not required to pass the savings on to patients. Instead, many have used the program to charge patients and employer-sponsored insurance enormous markups, effectively turning a safety-net program into a profit engine.
This profit engine is now funding a lifestyle far removed from patient care. For instance, VCU’s Arts in Healthcare exhibit is valued at over $5 million. For a hospital system that benefits from a program meant to help low-income patients access affordable medicine, such spending raises obvious questions. Every dollar tied up in luxury branding is a dollar not going toward lowering costs for the people the 340B program was intended to serve.
Other institutions, such as Petersburg Medical Center and NYU Langone, have also solicited artwork for their facilities, while Mayo Clinic has partnered with a wellness and spa center. These are massive expenses that could be allocated to patient care, but instead, they are being used for opulent branding and luxury amenities.
Corporate Exploitation and the Role of Service Partners
The 340B windfall is not only funding brand upgrades and spa properties; it is also being treated as a revenue stream by large corporations. Take Cigna, for example, whose CEO described the company not as a direct participant but as a “service partner” to hospitals managing their 340B activity. Similarly, Nextplat, a publicly traded healthcare e-commerce platform, reported that its pharmacy 340B contract revenue decreased by approximately $6.4 million from 2024 to 2025, citing certain relationships transitioning to other pharmacy partners and some entities opening in-house pharmacies.
These developments underscore the growing concern that the 340B program is being misused by both hospitals and corporations, with the ultimate cost falling on patients and taxpayers.
Trump’s Push for Reform and Accountability
The Trump administration and Vice President JD Vance have been vocal about cracking down on fraud and wasteful spending. Recently, 445 defendants were charged with $6.5 billion in alleged fraud related to government healthcare programs. Regulators are urged to build on this momentum and turn their attention to the 340B program.
One step forward has been the Trump administration’s pilot program that would replace automatic upfront 340B discounts with a rebate model for a limited number of drugs. This initiative aims to bring more transparency and accountability into the process. Congress and the administration are encouraged to work together to support the reformed 340B pilot program, ensuring that taxpayer dollars are used to provide quality, affordable care rather than funding unnecessary extravagance.
As the administration moves forward with these reforms, the focus remains on addressing the systemic issues within the 340B program and preventing its misuse. The ultimate goal is to ensure that the program continues to serve its intended purpose: providing affordable healthcare to those in need.
Source: Breitbart
